Company research
Alamar Biosciences, Inc.
CIK 2104204Updated Nov 6, 2026
SecurityALMR · NASDAQ · equity
ALMR price & chart
Loading TradingView…
NASDAQ:ALMR on TradingView ↗About the company
We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics.
In the news
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 ↗
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ ↗
Seeking Alpha
Alamar Biosciences, Inc. (ALMR) Presents at 2026 UBS Global Healthcare Conference Transcript ↗
Alamar Biosciences: Recurring Revenue Potential At A High Premium ↗
Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript ↗
SEC disclosures
Alamar Biosciences, Inc. files 8-K: Material Event ↗
Recent filings
Offerings
Registration 333-294697
- Gross proceeds
- 191250000.0
- Net proceeds
- 177862500.0
- Deal price
- 17.0
- Shares
- 11250000
- Offering price
- $17.00
- Ticker
- ALMR
Underwriters: Participants(1), Illumina Innovation Fund II, L.P.(2), Sands Capital Life Sciences Pulse Fund II, L.P.(3)
Registration 333-295116
Filing attachments
ck0002104204-ex99_1.htm · 8-K · 2026-11-03
Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026. Recent Highlights • Generated $33.5 million of total revenue for the third quarter of 2026, an increase of 68% as compared to the …
Read attachment ↗ck0002104204-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 ck0002104204-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance FREMONT, Calif.--August 10, 2026 (GLOBE NEWSWIRE) - Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended June 30, 2026. Recent Highlights • Generated $29.4 million of total revenue for the second…
Read attachment ↗ck0002104204-ex99_1.htm · 8-K · 2026-05-08
EX-99.1 2 ck0002104204-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alamar Biosciences Reports First Quarter 2026 Financial Results FREMONT, Calif.--(GLOBE NEWSWIRE) - Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent Highlights • Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to …
Read attachment ↗d39680dex42.htm · S-1 · 2026-03-27
EX-4.2 4 d39680dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of the February 21, 2024, by and among ALAMAR BIOSCIENCES, INC., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor” and collectively as the “Investors” and the holders of Class A Common Stock (as defined …
Read attachment ↗d39680dex43.htm · S-1 · 2026-03-27
EX-4.3 5 d39680dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 Execution Version THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATIO…
Read attachment ↗